Free Trial

Bon Natural Life (BON) Competitors

Bon Natural Life logo
$1.92 +0.04 (+2.13%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.93 +0.01 (+0.52%)
As of 10/24/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BON vs. GRTX, VCNX, ASLN, ZVSA, AKAN, NMTR, HSTO, NKGN, HEPA, and PTPI

Should you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Galera Therapeutics (GRTX), Vaccinex (VCNX), ASLAN Pharmaceuticals (ASLN), ZyVersa Therapeutics (ZVSA), Akanda (AKAN), 9 Meters Biopharma (NMTR), Histogen (HSTO), NKGen Biotech (NKGN), Hepion Pharmaceuticals (HEPA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "pharmaceutical products" industry.

Bon Natural Life vs. Its Competitors

Galera Therapeutics (NASDAQ:GRTX) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Galera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.35, indicating that its stock price is 135% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Bon Natural Life N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Galera Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 3 mentions for Galera Therapeutics and 2 mentions for Bon Natural Life. Galera Therapeutics' average media sentiment score of 0.15 beat Bon Natural Life's score of 0.00 indicating that Galera Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Galera Therapeutics Neutral
Bon Natural Life Neutral

Bon Natural Life has higher revenue and earnings than Galera Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M-$0.19-0.12
Bon Natural Life$23.84M0.65$400KN/AN/A

Summary

Bon Natural Life beats Galera Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

MetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ Exchange
Market Cap$15.28M$2.34B$8.43B$10.66B
Dividend YieldN/A4.55%3.07%4.82%
P/E RatioN/A17.5619.4030.34
Price / Sales0.656.966.44134.75
Price / Cash0.1815.1216.4861.44
Price / Book0.011.614.946.60
Net Income$400K$106.26M$255.94M$276.82M
7 Day Performance-4.00%0.71%2.07%2.53%
1 Month PerformanceN/A-4.09%-1.38%3.71%
1 Year PerformanceN/A-13.44%39.94%33.82%

Bon Natural Life Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
0.7692 of 5 stars
$1.92
+2.1%
N/AN/A$15.28M$23.84M0.00100Analyst Forecast
Short Interest ↓
GRTX
Galera Therapeutics
0.9264 of 5 stars
$0.02
+4.4%
N/A-56.2%$1.26MN/A-0.0530Gap Up
VCNX
Vaccinex
0.7965 of 5 stars
$0.48
flat
N/A-74.1%$1.24M$388K-0.0140
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12M-0.0330
ZVSA
ZyVersa Therapeutics
N/A$0.14
+3.6%
N/A-92.3%$1.07MN/A0.002
AKAN
Akanda
0.7736 of 5 stars
$2.29
+2.7%
N/A-60.7%$1.05M$840K0.00110Gap Up
High Trading Volume
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/A0.0020
HSTO
Histogen
N/A$0.00
flat
N/AN/A$918K$19K0.0020
NKGN
NKGen Biotech
N/A$0.02
+81.8%
N/A-94.8%$899KN/A0.00N/A
HEPA
Hepion Pharmaceuticals
0.2426 of 5 stars
$0.07
-10.1%
N/A-99.8%$812KN/A-0.0220Negative News
PTPI
Petros Pharmaceuticals
N/A$0.02
-2.5%
N/A-99.8%$729K$5.11M0.0020Gap Down

Related Companies and Tools


This page (NASDAQ:BON) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners